

## Variant: *NM\_000546.5(TP53):c.743G>T (p.Arg248Leu)*

Version: 1.1

[CA10580924](#) 

[230253 \(ClinVar\)](#) 

**Gene:** TP53 ([HGNC:7157](#))

**Condition:** Li-Fraumeni syndrome ([MONDO:0018875](#))

**Inheritance Mode:** Autosomal dominant inheritance

**UUID:** 291eceb4-ecb0-489a-b637-b9ff4f5f34d5

**Approved on:** 2024-08-05

**Published on:** 2024-08-05

### *HGVS expressions*

**NM\_000546.5:c.743G>T**

NM\_000546.5(TP53):c.743G>T (p.Arg248Leu)

NC\_000017.11:g.7674220C>A

CM000679.2:g.7674220C>A

NC\_000017.10:g.7577538C>A

CM000679.1:g.7577538C>A

NC\_000017.9:g.7518263C>A

NG\_017013.2:g.18331G>T

ENST00000503591.2:c.743G>T

ENST00000508793.6:c.743G>T

ENST00000509690.6:c.347G>T

ENST00000514944.6:c.464G>T

ENST00000604348.6:c.722G>T

ENST00000269305.9:c.743G>T

ENST00000269305.8:c.743G>T

ENST00000359597.8:c.743G>T

ENST00000413465.6:c.743G>T

ENST00000420246.6:c.743G>T

ENST00000445888.6:c.743G>T

ENST00000455263.6:c.743G>T

ENST00000504290.5:c.347G>T

ENST00000504937.5:c.347G>T

ENST00000509690.5:c.347G>T

ENST00000510385.5:c.347G>T

ENST00000514944.5:c.464G>T

ENST00000610292.4:c.626G>T

ENST00000610538.4:c.626G>T

ENST00000610623.4:c.266G>T

ENST00000615910.4:c.710G>T

ENST00000617185.4:c.743G>T

ENST00000618944.4:c.266G>T

ENST00000619186.4:c.266G>T

ENST00000619485.4:c.626G>T

ENST00000620739.4:c.626G>T

ENST00000622645.4:c.626G>T

ENST00000635293.1:c.626G>T

NM\_001126112.2:c.743G>T

NM\_001126113.2:c.743G>T  
NM\_001126114.2:c.743G>T  
NM\_001126115.1:c.347G>T  
NM\_001126116.1:c.347G>T  
NM\_001126117.1:c.347G>T  
NM\_001126118.1:c.626G>T  
NM\_001276695.1:c.626G>T  
NM\_001276696.1:c.626G>T  
NM\_001276697.1:c.266G>T  
NM\_001276698.1:c.266G>T  
NM\_001276699.1:c.266G>T  
NM\_001276760.1:c.626G>T  
NM\_001276761.1:c.626G>T  
NM\_001276695.2:c.626G>T  
NM\_001276696.2:c.626G>T  
NM\_001276697.2:c.266G>T  
NM\_001276698.2:c.266G>T  
NM\_001276699.2:c.266G>T  
NM\_001276760.2:c.626G>T  
NM\_001276761.2:c.626G>T  
NM\_000546.6:c.743G>T  
NM\_001126112.3:c.743G>T  
NM\_001126113.3:c.743G>T  
NM\_001126114.3:c.743G>T  
NM\_001126115.2:c.347G>T  
NM\_001126116.2:c.347G>T  
NM\_001126117.2:c.347G>T  
NM\_001126118.2:c.626G>T  
NM\_001276695.3:c.626G>T  
NM\_001276696.3:c.626G>T  
NM\_001276697.3:c.266G>T  
NM\_001276698.3:c.266G>T  
NM\_001276699.3:c.266G>T  
NM\_001276760.3:c.626G>T  
NM\_001276761.3:c.626G>T

**Pathogenic**

**Met criteria codes** 9

PS3 PS4\_Supporting PP3\_Moderate  
PP1 PS2\_Supporting PP4\_Moderate  
PM1 PM2\_Supporting PM5\_Strong

**Not Met criteria codes** 7

PS1 BP4 BA1 BS2 BS1 BS4  
BS3

**Evidence Links** 0

**Expert Panel**

[TP53 VCEP](#)

**Criteria Specification Information**

[Criteria Specification:](#) *ClinGen TP53 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for TP53 Version 2.0.0*

[Criteria Specification Approval History](#)















[Criteria Specifications for this VCEP](#)





Evidence submitted by expert panel

## TP53 VCEP















The NM\_000546.6: c.743G>T variant in TP53 is a missense variant predicted to cause substitution of arginine by leucine at amino acid 248 (p.Arg248Leu). This variant has been reported in 3 unrelated probands meeting Revised Chompret criteria. Based on this evidence, this variant scores 1.5 total points meeting the TP53 VCEP phenotype scoring criteria of of 1-1.5 points. (PS4\_Supporting; PMIDs 1359493, 25584008, ClinVar SCV SCV000273723.7, Internal lab contributor). This variant has been identified as a de novo occurrence with unconfirmed parental relationships in an individual with a moderately LFS-associated cancer totaling 1 phenotype point (PS2\_Supporting; Internal lab contributors: SCV000273723.7). The variant has been reported to segregate with LFS-associated cancers in 3-4 meioses in 1 family (PP1; PMID: 1359493). At least two individuals with this variant were found to have a variant allele fraction of 5-25%, which is a significant predictor of variant pathogenicity (PP4\_Moderate, PMID: 34906512, Internal lab contributors: SCV000273723.7). In vitro assays performed in yeast and human cell lines showed non-functional transactivation and loss of growth suppression activity indicating that this variant impacts protein function (PMIDs: 12826609, 30224644, 29979965) (PS3). Two different missense variants, c.743G>A; p.Arg248Gln and c.742C>T; p.Arg248Trp, ClinVar IDs 12347 and 12356, in the same codon have been classified as pathogenic for Li-Fraumeni syndrome by the ClinGen TP53 VCEP's specifications. (PM5\_Strong). This variant resides within a codon (NM\_00546.4: 175, 245, 248, 249, 273, 282) of TP53 that is defined as a mutational hotspot by the ClinGen TP53 VCEP (PM1; PMID: 8023157). This variant is absent from gnomAD v4.1.0 (PM2\_Supporting). Computational predictor scores (BayesDel = 0.570318; Align GVG D = Class C65) are above recommended thresholds (BayesDel > 0.16 and an Align GVG D Class of 65), evidence that correlates with impact to TP53 via protein change (PP3\_Moderate). In summary, TP53 c.743G>T; p.Arg248Leu meets criteria to be classified as Pathogenic for Li-Fraumeni syndrome. ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: PS4\_Supporting, PS2\_Supporting, PP1, PP4\_Moderate, PS3, PM5\_Strong, PM1, PM2\_Supporting, PP3\_Moderate. (Bayesian Points: 18; VCEP specifications version 2.0; 7/24/2024)

### Met criteria codes

<b>PS3</b>			In vitro assays performed in yeast and/or human cell lines showed non-functional transactivation and loss of growth suppression activity indicating that this variant impacts protein function (PMIDs: 12826609, 30224644, 29979965) (PS3).
<b>PS4_Supporting</b>			This variant has been reported in 3 unrelated probands meeting Revised Chompret criteria, respectively. Based on this evidence, this variant scores 1.5 total points meeting the TP53 VCEP phenotype scoring criteria of of 1-1.5 points. (PS4_Supporting; PMIDs 1359493, 25584008, ClinVar SCV SCV000273723.7, Internal lab contributor).
<b>PP3_Moderate</b>			Computational predictor scores (BayesDel = 0.570318; Align GVG D = Class C65) are above recommended thresholds (BayesDel > 0.16 and an Align GVG D Class of 65), evidence that correlates with impact to TP53 via protein change (PP3_Moderate).
<b>PP1</b>			The variant has been reported to segregate with LFS-associated cancers in 3-4 meioses in 1 family (PP1; PMID: 1359493).
<b>PS2_Supporting</b>			This variant has been identified as a de novo occurrence with unconfirmed parental relationships in an individual with a moderately LFS-associated cancer totaling 1 phenotype point (PS2_Supporting; Internal lab contributors: SCV000273723.7).
<b>PP4_Moderate</b>			At least two individuals with this variant were found to have a variant allele fraction of 5-25%, which is a significant predictor of variant pathogenicity (PP4_Moderate, PMID: 34906512, Internal lab contributors: SCV000273723.7).
<b>PM1</b>			This variant resides within a codon (NM_00546.4: 175, 245, 248, 249, 273, 282) of TP53 that is defined as a mutational hotspot by the ClinGen TP53 VCEP (PMID: 8023157 ) (PM1).

<b>PM2_Supporting</b>			This variant is absent from gnomAD v4.1.0 (PM2_Supporting).
<b>PM5_Strong</b>			Two different missense variants, c.743G>A; p.Arg248Gln and c.742C>T; p.Arg248Trp, ClinVar IDs 12347 and 12356, in the same codon have been classified as pathogenic for Li-Fraumeni syndrome by the ClinGen TP53 VCEP's specifications. (PM5_Strong).

**Not Met criteria codes**

<b>PS1</b>			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BP4</b>			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BA1</b>			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BS2</b>			Absent in FLOSSIES.
<b>BS1</b>			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BS4</b>			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BS3</b>			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

Curation History 

Showing 1 to 2 of 2 rows

--	--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.

---

[ClinGen Terms of Use.](#)  
⌘ [Powered by BCM's Genboree.](#)